10 results about "Tuberculosis prevention" patented technology

The invention provides a disease burden prediction and prevention and control decision-making method and system based on machine learning, and relates to the technical field of disease prediction and public health decision-making, and the method comprises the steps: obtaining epidemiological data of tuberculosis and related diseases from an authoritative database, and carrying out the preprocessing of the epidemiological data; respectively training an XGBoost model, an RF (Radio Frequency) model and a Prophet model; training a random forest meta-model by adopting a Stacking fusion strategy, and constructing a hybrid prediction model; calculating RMSE, MAE, MAPE and Rindex evaluation model performance; based on the obtained hybrid prediction model; based on the variable importance analysis result and the prediction result, the influence of the key independent variable on the tuberculosis burden dependent variable is quantified, the effect of the independent variable change on the dependent variable is simulated, and a tuberculosis prevention and control intervention strategy suggestion is generated. By fusing multi-source data and a hybrid modeling technology, tuberculosis prediction precision is remarkably improved, confidence interval quantization and prevention and control strategies are linked for the first time, and data-driven decision support is provided for global tuberculosis prevention and control.

This invention provides a data storage method and system for tuberculosis detection, relating to the field of tuberculosis detection technology. The data storage method for tuberculosis detection includes the following steps: S1. Collecting whole-genome sequencing data of Mycobacterium tuberculosis, host serum IgG titer, and drug sensitivity test results; S2. Calculating genetic distance D based on a reverse evolution model to generate four-dimensional spatiotemporal coordinates (t, x, y); S3. Performing data partitioning and storage based on the drug target barrier value β; S4. Generating dynamic metadata using a host-pathogen dynamics model and compressing and storing it. This invention implements a dynamic storage entropy adjustment algorithm at the hardware and software collaborative level, continuously optimizing the matching efficiency of data compression and physical storage. This results in an intelligent data hub that can perceive the evolutionary pulse of pathogens and autonomously optimize resources, providing support for clinical tuberculosis prevention and control decisions with temporal depth, spatial correlation, and risk evolution.

The invention relates to the field of vaccines, in particular to application of a bacillus calmette-guerin vaccine and a complete freund's adjuvant in preparation of tuberculosis prevention vaccines. The invention provides a novel inoculation strategy of subcutaneous combined inoculation of the bacillus calmette guerin vaccine and the complete freund's adjuvant, the safety consistent with that of the existing tuberculosis prevention vaccine in the clinical stage is achieved, and the immune protection effect higher than that of the existing tuberculosis prevention vaccine in the clinical stage and the preclinical research stage is achieved. The compound is expected to be used as a novel tuberculosis vaccine for preventing tuberculosis.

The invention discloses a Mycobacterium tuberculosis epitope mRNA (messenger Ribonucleic Acid) vaccine simulated, predicted and screened by a computer, which is prepared by the following steps: bacterial protein sequence acquisition and signal peptide analysis: acquiring amino acid sequences of proteins ESAT6, CFP10, Ag85A, Ag85B, TB10.4, PPE68, PPE18 and Rv1813c through a database; the method comprises the following steps: analyzing physicochemical properties of proteins, including the number of amino acids, the molecular weight, the instability index and the overall average value of water solubility, analyzing and predicting the allergy of the epitopes by using a server, and generating all potential mutants by using the server to predict and measure the toxicity of the epitopes; the multi-epitope mRNA vaccine candidate is successfully constructed by adopting computer simulation screening and optimization of the mycobacterium tuberculosis multi-epitope antigen, the vaccine design scheme is efficient, controllable and broad-spectrum, a theoretical basis and a candidate construct are provided for early research and development of tuberculosis vaccines, and the vaccine is expected to be used for prevention and control of tuberculosis and has positive influence on public health.

The invention is applicable to the field of gene engineering, and provides a mycobacterium tuberculosis PPE18-LS protein nanoparticle, a preparation method and application thereof, the mycobacterium tuberculosis PPE18-LS protein nanoparticle is formed by sequence fusion of mycobacterium tuberculosis PPE18 protein and LS protein, and the amino acid sequence of the mycobacterium tuberculosis PPE18-LS protein nanoparticle is shown as SEQ ID NO: 2 in a sequence table. According to the invention, the key protective antigen PPE18 of mycobacterium tuberculosis and the LS protein with self-assembly characteristic are subjected to fusion expression, and the PPE18-LS protein nanoparticles with uniform structure are successfully prepared through an Escherichia coli expression system. In-vivo experiment results show that the PPE18-LS protein nanoparticles can effectively activate response pathways of humoral immunity and cellular immunity of a host, show obvious protective efficacy in a mouse model, provide an important technical path for developing a new generation of tuberculosis preventive vaccines, and have wide clinical application prospects and industrialization values.

An aspect provides a vaccine composition for preventing tuberculosis comprising chorismate mutase. The vaccine composition alone may induce immunity specific to Mycobacterium tuberculosis, and when provided together with an immune adjuvant, the vaccine composition may induce immunity specific to tuberculosis more effectively. Furthermore, when an existing vaccine for tuberculosis is used as a prime and the vaccine composition according to an aspect including chorismite mutase is provided as a booster, the immunity specific to tuberculosis may be induced significantly more effectively.

The application discloses a fusion protein PP13138R and application thereof in tuberculosis prevention. Specifically disclosed is a fusion protein comprising HTL, CTL and B cell epitopes in series, PorB, PADRE and RS-09. The application screens 34 epitopes for Mycobacterium tuberculosis, which have good immunogenicity and antigenicity and no toxicity and no sensitization, and have the characteristics of high population coverage and the like. The auxiliary peptide PADRE is further added to improve the immunogenicity of the vaccine, and the PorB and RS-09 are added to endow the vaccine with a targeted delivery function. In-vitro experiments prove that the PP13138R can stimulate human peripheral blood mononuclear cells to produce an immune response, and is an advantage protective antigen. The PP13138R has the advantages of simple preparation method, low cost, high yield and higher safety as a vaccine. The application has great value for the prevention and treatment of active tuberculosis and latent tuberculosis infection.

The application relates to the technical field of biological medicine, in particular to a tuberculosis vaccine antigen and a vaccine. Specifically, the application provides an application of a mycobacterium tuberculosis Rv1787 gene in preparation of a vaccine for preventing and / or treating tuberculosis, and the application is characterized in that the sequence of the Rv1787 gene or a coded product thereof is determined, wherein the Rv1787 gene and the coded product thereof are used as antigens, have mycobacterium tuberculosis specificity, can precisely stimulate the immune system of the body to recognize and respond to the mycobacterium tuberculosis, avoid non-specific immune reactions to other normal tissues, provide a new specific molecular target for preventing and treating tuberculosis, and break through the limitation of traditional vaccines depending on single antigens or attenuated strains. The specific expression product of the gene can stimulate the immune system of the body to directionally recognize and attack the mycobacterium tuberculosis, significantly improves the pertinence and effectiveness of the vaccine, and provides a new path for solving the tuberculosis prevention and treatment problem.

The application discloses a fusion protein HP13138PB and application thereof in tuberculosis prevention. Specifically disclosed is a fusion protein comprising HTL, CTL and B cell epitopes in series, HBD-3, PSM alpha 4 and PADRE. The application screens 34 epitopes for mycobacterium tuberculosis, which have good immunogenicity and antigenicity and no toxicity and sensitization, and have the characteristics of high population coverage and the like. The immunogenicity of the vaccine is improved by further adding antibacterial peptide HBD-3 and auxiliary peptide PADRE, and PSM alpha 4 is added to endow the vaccine with targeted delivery function. In-vitro experiments prove that HP13138PB can stimulate human peripheral blood mononuclear cells to produce an immune response, and is an advantage protective antigen. The HP13138PB as a vaccine has the advantages of simple preparation method, low cost, high yield and higher safety and the like. The application has great value for the prevention and treatment of active tuberculosis and latent tuberculosis infection.

This invention discloses the polypeptide fusion protein CP13138P and its application in tuberculosis prevention. Specifically, it discloses a fusion protein comprising tandem HTL, CTL, and B-cell epitopes, CTB, Pam2Cys, and PADRE. This invention screened 34 epitopes targeting Mycobacterium tuberculosis, which exhibit excellent immunogenicity and antigenicity, are non-toxic and non-sensitizing, and have high population coverage. In vitro experiments demonstrate that CP13138P can stimulate an immune response in human peripheral blood mononuclear cells (PBMCs), increasing IFN-γ in PBMCs. + The number of T lymphocytes is significantly increased, and they secrete significantly high levels of more than a dozen cytokines, including G-CSF, making them a dominant protective antigen. CP13138P, as a vaccine, has advantages such as simple preparation method, low cost, high yield, and enhanced safety. This invention has significant value for the prevention and treatment of active tuberculosis and latent tuberculosis infection.